Impact of catalytic iron on mortality in patients with acute coronary syndrome exposed to iodinated radiocontrast—The Iscom Study - 26/04/13
, Banibrata N. Mukhopadhyay, MSc, PhD b, Mohan M. Mardikar, DM c, Tejas A. Patel, DM d, Apoorva K. Vasavada, DM e, Darshan N. Banker, DM f, Ketan D. Kapasi, DNB a, Virendra C. Chauhan, MD a, Kamaldeep C. Chawla, DNB g, Soma R. Raju, DM e, Shirish S. Hiremath, DM h, Sashi S. Chinchole, PhD b, Mohan M. Rajapurkar, MD bRésumé |
Background |
Catalytic iron (CI) mediates vascular injury by generating reactive oxygen species. We evaluated role of CI in predicting mortality in patients with acute coronary syndrome (ACS) and studied association of contrast nephropathy with CI levels.
Methods |
We investigated 806 patients with ACS undergoing contrast exposure for a cardiac procedure who were followed up for 30 days.
Results |
Overall mortality was 1.6% at 30 days. Catalytic iron at baseline predicted mortality with CI levels significantly higher in those who died, 0.45 μmol/L (0.37, 0.68) compared with survivors 0.31 μmol/L (0.21, 0.40); P = .004. Catalytic iron was associated with increased risk of death in the highest quartile compared with lower 3 quartiles (hazard ratio 7.88, P = .001) after adjustment for age, diabetes, ST deviation, Killip class, ejection fraction, baseline creatinine, hemoglobin level, and troponin. Fifty-five patients (6.8%) developed contrast nephropathy. Patients with contrast nephropathy had a 27% increase in median CI levels from baseline up to 48 hours compared with a marginal 2.9% increase in those without contrast nephropathy (0.37, 0.14 μmol/L to 0.47, 0.20 μmol/L versus 0.35, 0.12 μmol/L to 0.36, 0.14 μmol/L, P < .0001). Patients with contrast nephropathy had significantly higher mortality compared with those without contrast nephropathy (9.1% vs 1.1%, P = .001).
Conclusion |
High baseline CI levels predicted mortality in patients with ACS. Occurrence of contrast nephropathy was associated with rise in CI levels and higher mortality. Therapeutic options to buffer or chelate CI may have beneficial effects on mortality in this setting.
Le texte complet de cet article est disponible en PDF.Plan
Vol 165 - N° 5
P. 744-751 - mai 2013 Retour au numéro
Article précédent
- Randomized trial comparing the efficacy between different types of paclitaxel-eluting stents: The comparison of Efficacy between COroflex PLEASe ANd Taxus stent (ECO-PLEASANT) randomized controlled trial
- Jae-Bin Seo, Si-Hyuck Kang, Seung-Ho Hur, Kyung Woo Park, Tae-Jin Youn, Jong-Seon Park, Han-Mo Yang, Hae-Young Lee, Hyun-Jae Kang, Bon-Kwon Koo, Jang-Ho Bae, Sang-Wook Kim, Keon-Woong Moon, Jae-Woong Choi, Sang-Gon Lee, Woo-Young Chung, Soo-Joong Kim, Doo-Il Kim, Byung-Ok Kim, Min-Su Hyon, Keum-Soo Park, Tae-Joon Cha, Chul-Woong Yoo, Hui-Kyung Jeon, Hyo-Soo Kim
- Impact of preoperative chronic kidney disease on short- and long-term outcomes after transcatheter aortic valve implantation: A Pooled-RotterdAm-Milano-Toulouse In Collaboration Plus (PRAGMATIC-Plus) initiative substudy
- Nicolas Dumonteil, Robert M.A. van der Boon, Didier Tchetche, Alaide Chieffo, Nicolas M. Van Mieghem, Bertrand Marcheix, Gill L. Buchanan, Olivier Vahdat, Patrick W. Serruys, Jean Fajadet, Antonio Colombo, Peter P.T. de Jaegere, Didier Carrié
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?